Navigation Links
Wyeth's Torisel and Roche/Genentech's Avastin Will Challenge Pfizer's Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
Date:8/19/2007

Increased Survival Rates and Decreased Disease Progression Rates Are the

Advantages, According to a New Report from Decision Resources

WALTHAM, Mass., Aug. 7 /PRNewswire/ -- Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Wyeth's Torisel and Roche/Genentech's Avastin will challenge Pfizer's Sutent as the clinical gold standard for the treatment of metastatic renal cell carcinoma. According to the new report entitled Two Hot New Drugs Battle for Top Position: A Renal Cell Carcinoma Study, both Torisel and Avastin offer increased overall survival rates as well as decreased disease progression times.

"Metastatic renal cell carcinoma is an end-stage disease in which the primary goal of treatment is to prolong survival," said Mohamed Muhsin, analyst at Decision Resources. "Phase III clinical trials have shown Torisel to increase the median overall survival rates of patients by 49 percent. High rates of partial response and stable disease, extended median time to progression, and overall survival rates for patients on Torisel are promising. Phase II trials for Avastin have shown that 61% of patients had stable disease. The median progression-free survival rate was eleven months, and the one-year progression-free survival rates for patients with objective response, minor response, and stable disease were 80%, 57% and 27%, respectively."

About Two Hot New Drugs Battle for Top Position: A Renal Cell Carcinoma Study

Two Hot New Drugs Battle for Top Position: A Renal Cell Carcinoma Study covers the current and future state of the metastatic renal cell carcinoma drug market. The report includes the following:

-- More than 3,000 physician responses that define drug attributes that

drive prescription now and in the future.

* Clinical end point tradeoffs that are most influential to

physicians.

* Areas of unmet need with highest potential.

* Benchmark trial results for specific drug opportunities.

* Patient share potential for emerging therapies and target product

profiles.

-- Decision Resources proprietary analysis of commercial factors that

accelerate or constrain a drug's market potential.

* Promotion: DTC spend, detailing intensity.

* Reimbursement: formulary tier, prior approval restriction, quantity

limits.

* Labeling: black box warnings, approved patient segments,

contraindications.

* Competition: order of entry, pricing, generic entry, pipeline sales

forecast.

* Medical practice: decision trees, treating physician type, line of

therapy.

-- Comparisons of the key clinical attributes of current and emerging

therapies in the areas of efficacy, safety, and delivery.

-- Analysis and supporting data that identifies the clinical "Gold

Standard" now and over the next ten years.

-- Key insights as to which clinical end points have the greatest

influence on physician decision-making.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources, Inc., (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources, Inc.

Copyright©2007 PR Newswire.

Related medicine technology :

1. Biotheras Imprime PGG Enhanced Effectiveness of Avastin in Cancer Study
2. FDA MedWatch: Avastin (bevacizumab) and Formation of Tracheoesophageal Fistula in a Recent Clinical Study in Patients with Limited-stage Small Cell Lung Cancer
3. Data Presented at AACR Meeting Shows Peregrines Selective Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical Cancer Models
4. Neuroblastoma Expert Reviews Progress and Challenges in Fighting Difficult Pediatric Cancer
5. Novavax Pandemic Flu Vaccine Provided Protection Against a Lethal Challenge of Live Virus, Pre-Clinical Data Show
6. Annual Meeting of the Consortium of Multiple Sclerosis Centers Focuses on the Challenges of Care and Research in Multiple Sclerosis
7. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
8. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
9. Novavax Reports Positive Pre-Clinical Study Results from Live Virus Challenge to Pandemic Flu Vaccine
10. LigoCyte Pharmaceuticals Presents Data Showing Heterosubtypic Protection Against Influenza Challenge With Virus-Like Particle Immunization
11. Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016  MedSource announced today ... its e-clinical software solution of choice.  This latest ... possible value to their clients by offering a ... preferred relationship establishes nowEDC as the EDC platform ... MedSource,s full-service clients.  "nowEDC has long been a ...
(Date:6/23/2016)... 2016 Any dentist who has made an implant ... process. Many of them do not even offer this as ... high laboratory costs involved. And those who ARE able to ... a high cost that the majority of today,s patients would ... Parsa Zadeh , founder of Dental Evolutions Inc. and inventor ...
(Date:6/23/2016)... Ill. , June 23, 2016  In a startling report ... are failing their residents by lacking a comprehensive, proven plan to ... a definitive ranking of how states are tackling the worst ... to only four states – Kentucky , ... Vermont . Of the 28 failing states, three ...
Breaking Medicine Technology:
(Date:6/26/2016)... N.J. (PRWEB) , ... June 27, 2016 , ... Quality ... sources, yet in many ways they remain in the eye of the beholder, according ... (EBO), a publication of The American Journal of Managed Care. For the full issue, ...
(Date:6/26/2016)... , ... June 26, 2016 , ... PawPaws brand ... new product that was developed to enhance the health of felines. The formula is ... The two main herbs in the PawPaws Cat Kidney Support Supplement Soft ...
(Date:6/25/2016)... ... 25, 2016 , ... Experts from the American Institutes for ... Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR ... care planning, healthcare costs and patient and family engagement. , AIR researchers will ...
(Date:6/25/2016)... , ... June 25, 2016 , ... "With 30 hand-drawn ... specific project," said Christina Austin - CEO of Pixel Film Studios. , ProHand ... all within Final Cut Pro X . Simply select a ProHand generator and ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
Breaking Medicine News(10 mins):